As of 1 January 2008, The International Task Force on Canine Atopic Dermatitis was composed, in alphabetical order, of Emmanuel Bensignor (F), Didier Carlotti (F), Douglas J DeBoer (USA), Claude Favrot (CH), Craig Griffin (USA), Richard Halliwell (Chair; UK), Bruce Hammerberg (USA), Peter Hill (UK), Toshiroh Iwasaki (J), Hilary Jackson (UK), Sadatoshi Maeda (J), Kenichi Masuda (J), Rosanna Marsella (USA), Ralf Mueller (D), Tim Nuttall (UK), Thierry Olivry (USA), Pascal Prélaud (F), Candace Sousa (USA) and Ton Willemse (NL).
Determination of CADESI-03 thresholds for increasing severity levels of canine atopic dermatitis
Article first published online: 11 APR 2008
© 2008 The Authors. Journal compilation © 2008 ESVD and ACVD
Volume 19, Issue 3, pages 115–119, June 2008
How to Cite
Olivry, T., Mueller, R., Nuttall, T., Favrot, C., Prélaud, P. and for the International Task Force on Canine Atopic Dermatitis (2008), Determination of CADESI-03 thresholds for increasing severity levels of canine atopic dermatitis. Veterinary Dermatology, 19: 115–119. doi: 10.1111/j.1365-3164.2008.00668.x
- Issue published online: 28 JUN 2008
- Article first published online: 11 APR 2008
- Accepted 6 March 2008
To evaluate the extent and severity of skin lesions in clinical trials enrolling dogs with atopic dermatitis (AD), the International Task Force on Canine Atopic Dermatitis recently recommended the use of the third version of the CADESI. This version of the CADESI was found to exhibit acceptable content, construct, criterion, inter- and intraobserver reliability and sensitivity to change. The current study was aimed at determining optimal CADESI-03 cut-off points to separate AD severity categories for future clinical trials. One hundred and eight dogs with AD were selected based on current diagnosis standards. At one or more visits, clinicians subjectively rated the severity of AD as ‘in remission’, ‘mild’, ‘moderate’ or ‘severe’, and a CADESI-03 score was then determined. In all, 158 CADESI-03 values were recorded and divided among the four disease severity categories. Receiver-operating characteristics (ROC) curves were generated at increasing cut-off values to determine the benchmark that would offer optimal sensitivity and specificity between adjacent categories. Cut-offs of 16, 60 and 120 are proposed at the interface of remission, mild, moderate and severe categories, respectively. Proposed intervals therefore are: remission: 0–15; mild AD: 16–59; moderate AD: 60–119; and severe AD: ≥ 120. This Task Force recommends that, whenever applicable and relevant, subgroup analyses of outcome measures, based on disease severity as determined with these cut-off CADESI-03 values, be preplanned for clinical trials enrolling dogs with AD. Such subgroup analyses could help determine whether specific interventions might be more effective in a particular subset of atopic dogs.